- Home
- ANVS vs ATHA Comparison
ANVS vs ATHA Comparison
Compare ANVS & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- ATHA
- Stock Information
- Founded
- ANVS 2008
- ATHA 2011
- Country
- ANVS United States
- ATHA United States
- Employees
- ANVS N/A
- ATHA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- ANVS Health Care
- ATHA Health Care
- Exchange
- ANVS Nasdaq
- ATHA Nasdaq
- Market Cap
- ANVS 24.2M
- ATHA 21.0M
- IPO Year
- ANVS 2020
- ATHA 2020
- Fundamental
- Price
- ANVS $1.55
- ATHA $0.26
- Analyst Decision
- ANVS Strong Buy
- ATHA Buy
- Analyst Count
- ANVS 4
- ATHA 4
- Target Price
- ANVS $40.67
- ATHA $11.25
- AVG Volume (30 Days)
- ANVS 459.6K
- ATHA 204.2K
- Earning Date
- ANVS 05-20-2025
- ATHA 05-14-2025
- Dividend Yield
- ANVS N/A
- ATHA N/A
- EPS Growth
- ANVS N/A
- ATHA N/A
- EPS
- ANVS N/A
- ATHA N/A
- Revenue
- ANVS N/A
- ATHA N/A
- Revenue This Year
- ANVS N/A
- ATHA N/A
- Revenue Next Year
- ANVS N/A
- ATHA N/A
- P/E Ratio
- ANVS N/A
- ATHA N/A
- Revenue Growth
- ANVS N/A
- ATHA N/A
- 52 Week Low
- ANVS $1.11
- ATHA $0.22
- 52 Week High
- ANVS $17.88
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- ANVS 56.90
- ATHA 42.81
- Support Level
- ANVS $1.42
- ATHA $0.23
- Resistance Level
- ANVS $1.75
- ATHA $0.27
- Average True Range (ATR)
- ANVS 0.15
- ATHA 0.03
- MACD
- ANVS 0.04
- ATHA 0.00
- Stochastic Oscillator
- ANVS 84.62
- ATHA 27.53
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.